Skip to main content

Experimental therapeutics and drug development

This section covers all aspects of preclinical investigations on therapeutic agents. It welcomes submissions concerning anti-cancer drug discovery and development, and targeted therapies.

Page 12 of 12

  1. Multiple myeloma (MM) is a fatal malignancy ranking second in prevalence among hematological tumors. Continuous efforts are being made to develop innovative and more effective treatments. The preclinical evalu...

    Authors: Leonardo Mirandola, Yuefei Yu, Marjorie R Jenkins, Raffaella Chiaramonte, Everardo Cobos, Constance M John and Maurizio Chiriva-Internati

    Citation: BMC Cancer 2011 11:394

    Content type: Research article

    Published on:

  2. Single drug use has not achieved satisfactory results in the treatment of prostate cancer, despite application of increasingly widespread targeted therapeutics. In the present study, the combined impact of the...

    Authors: Steffen Wedel, Lukasz Hudak, Jens-Michael Seibel, Jasmina Makarević, Eva Juengel, Igor Tsaur, Ana Waaga-Gasser, Axel Haferkamp and Roman A Blaheta

    Citation: BMC Cancer 2011 11:375

    Content type: Research article

    Published on:

  3. Late stage Ovarian Cancer is essentially incurable primarily due to late diagnosis and its inherent heterogeneity. Single agent treatments are inadequate and generally lead to severe side effects at therapeuti...

    Authors: Preetinder P Singh, Swapna Joshi, Pamela J Russell, Sham Nair and Aparajita Khatri

    Citation: BMC Cancer 2011 11:368

    Content type: Research article

    Published on:

  4. The primary goal of current chemotherapy in hepatoblastoma (HB) is reduction of tumour volume and vitality to enable complete surgical resection and reduce risk of recurrence or metastatic disease. Drug resist...

    Authors: Justus Lieber, Carmen Eicher, Julia Wenz, Bettina Kirchner, Steven W Warmann, Jörg Fuchs and Sorin Armeanu-Ebinger

    Citation: BMC Cancer 2011 11:362

    Content type: Research article

    Published on:

  5. Transferrin receptor (TfR) is a cell membrane-associated glycoprotein involved in the cellular uptake of iron and the regulation of cell growth. Recent studies have shown the elevated expression levels of TfR ...

    Authors: Megumi Kawamoto, Tomohisa Horibe, Masayuki Kohno and Koji Kawakami

    Citation: BMC Cancer 2011 11:359

    Content type: Research article

    Published on:

  6. Nucleolin expressed at the cell surface is a binding protein for a variety of ligands implicated in tumorigenesis and angiogenesis. By using a specific antagonist that binds the C-terminal RGG domain of nucleo...

    Authors: Bernard Krust, Diala El Khoury, Isabelle Nondier, Calaiselvy Soundaramourty and Ara G Hovanessian

    Citation: BMC Cancer 2011 11:333

    Content type: Research article

    Published on:

  7. Polysaccharides extracted from the Phellinus linteus (PL) mushroom are known to possess anti-tumor effects. However, the molecular mechanisms responsible for the anti-tumor properties of PL remain to be explored....

    Authors: Kyoung-Sub Song, Ge Li, Jong-Seok Kim, Kaipeng Jing, Tae-Dong Kim, Jin-Pyo Kim, Seung-Bo Seo, Jae-Kuk Yoo, Hae-Duck Park, Byung-Doo Hwang, Kyu Lim and Wan-Hee Yoon

    Citation: BMC Cancer 2011 11:307

    Content type: Research article

    Published on:

  8. Targeting of the renin angiotensin system (RAS) reduces tumour growth in experimental models of cancer. We aimed to establish if combined targeting of the 'classical' and 'alternative' arms of the RAS could re...

    Authors: Eleanor I Ager, Shu Wen Wen, Joyna Chan, Way W Chong, Jaclyn H Neo and Christopher Christophi

    Citation: BMC Cancer 2011 11:274

    Content type: Research article

    Published on:

  9. Flaxseed (FS) is a dietary supplement known for its antioxidant and anti-inflammatory properties. Radiation exposure of lung tissues occurs either when given therapeutically to treat intrathoracic malignancies...

    Authors: Melpo Christofidou-Solomidou, Sonia Tyagi, Kay-See Tan, Sarah Hagan, Ralph Pietrofesa, Floyd Dukes, Evguenia Arguiri, Daniel F Heitjan, Charalambos C Solomides and Keith A Cengel

    Citation: BMC Cancer 2011 11:269

    Content type: Research article

    Published on:

  10. Cucurbitacin-I (JSI-124) is potent inhibitor of JAK/STAT3 signaling pathway and has anti-tumor activity in a variety of cancer including B cell leukemia. However, other molecular targets of JSI-124 beyond the ...

    Authors: Ganchimeg Ishdorj, James B Johnston and Spencer B Gibson

    Citation: BMC Cancer 2011 11:268

    Content type: Research article

    Published on:

  11. Cladribine or 2-chlorodeoxyadenosine (2-CDA) is a well-known purine nucleoside analog with particular activity against lymphoproliferative disorders, such as hairy cell leukemia (HCL). Its benefits in multiple...

    Authors: Jian Ma, Shuiliang Wang, Ming Zhao, Xin-Sheng Deng, Choon-Kee Lee, Xiao-Dan Yu and Bolin Liu

    Citation: BMC Cancer 2011 11:255

    Content type: Research article

    Published on:

  12. Aurora kinases play an essential role in orchestrating chromosome alignment, segregation and cytokinesis during mitotic progression, with both aurora-A and B frequently over-expressed in a variety of human mal...

    Authors: Martin Grundy, Claire Seedhouse, Nigel H Russell and Monica Pallis

    Citation: BMC Cancer 2011 11:254

    Content type: Research article

    Published on:

  14. Aromatase inhibitors (AI) that inhibit breast cancer cell growth by blocking estrogen synthesis have become the treatment of choice for post-menopausal women with estrogen receptor positive (ER+) breast cancer. H...

    Authors: Tesfom Abrhale, Angela Brodie, Gauri Sabnis, Luciana Macedo, Changsheng Tian, Binbin Yue and Ginette Serrero

    Citation: BMC Cancer 2011 11:231

    Content type: Research article

    Published on:

  15. Reovirus type 3 Dearing (T3D) has demonstrated oncolytic activity in vitro, in in vivo murine models and in early clinical trials. However the true potential of oncolytic viruses may only be realized fully in com...

    Authors: Lucy Heinemann, Guy R Simpson, Angela Boxall, Timothy Kottke, Kate L Relph, Richard Vile, Alan Melcher, Robin Prestwich, Kevin J Harrington, Richard Morgan and Hardev S Pandha

    Citation: BMC Cancer 2011 11:221

    Content type: Research article

    Published on:

  17. Hepatocellular carcinoma (HCC) usually has a dismal prognosis because of its limited response to current pharmacotherapy and high metastatic rate. Sulfated oligosaccharide has been confirmed as having potent a...

    Authors: Chun-Li Xiao, Zhong-Hua Tao, Lin Guo, Wei-Wei Li, Jin-Liang Wan, Hui-Chuan Sun, Lu Wang, Zhao-You Tang, Jia Fan and Wei-Zhong Wu

    Citation: BMC Cancer 2011 11:150

    Content type: Research article

    Published on:

  18. Curcumin is a naturally occurring phenolic compound shown to have a wide variety of antitumor activities; however, it does not attain sufficient blood levels to do so when ingested. Using structure-based desig...

    Authors: Stacey L Fossey, Misty D Bear, Jiayuh Lin, Chenglong Li, Eric B Schwartz, Pui-Kai Li, James R Fuchs, Joelle Fenger, William C Kisseberth and Cheryl A London

    Citation: BMC Cancer 2011 11:112

    Content type: Research article

    Published on:

  19. Treatment of tumors with macromolecular toxins directed to cytoplasmic targets requires selective endocytosis followed by release of intact toxin from the endosomal/lysosomal compartment. The latter step remai...

    Authors: Xiaoqin Yuan, Xinjian Lin, Gerald Manorek and Stephen B Howell

    Citation: BMC Cancer 2011 11:61

    Content type: Research article

    Published on:

Submit manuscript

Follow

BMC Cancer

ISSN: 1471-2407

Contact us